AMP's Victory Has 'Very Limited' Legal Effect But Carries 'Far-Reaching Implications'

A New York District Judge yesterday ruled that Myriad Genetics' BRCA1 and BRCA2 patents are invalid. Here are some key points about the decision as reported by a handful of key news and specialty outlets.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.